Healthcare – Karma https://karmaimpact.com Advancing people, planet and profit. Fri, 06 Dec 2019 21:19:24 +0000 en-US hourly 1 https://wordpress.org/?v=5.2.3 Magnetar Raising $400 Million for Healthcare Fund as Private Money Piles into Industry /magnetar-raising-400-million-for-healthcare-fund-as-private-money-piles-into-industry/ /magnetar-raising-400-million-for-healthcare-fund-as-private-money-piles-into-industry/#respond Fri, 06 Dec 2019 21:19:23 +0000 /?p=14168 Magnetar Capital, which has made billions on its energy and infrastructure bets, is joining others who are seeing green lights flashing in healthcare. The $13.4 billion hedge fund is seeking to raise $400 million, Bloomberg reported, citing a person familiar. The Evanston, Illinois-based firm is planning to close the fundraising by mid-2020, and focus on […]

The post Magnetar Raising $400 Million for Healthcare Fund as Private Money Piles into Industry appeared first on Karma.

]]> /magnetar-raising-400-million-for-healthcare-fund-as-private-money-piles-into-industry/feed/ 0 Amazon Debuts Service Enabling Doctors to Dictate Notes in Real Time /amazon-debuts-service-enabling-doctors-to-dictate-notes-in-real-time/ /amazon-debuts-service-enabling-doctors-to-dictate-notes-in-real-time/#respond Mon, 02 Dec 2019 21:03:21 +0000 /?p=13992 Amazon’s latest step in using technology to make healthcare more effective is simple: A voice-technology service that enables medical providers to spend more time with patients.The service, called Amazon Transcribe Medical, enables doctors to quickly dictate their notes into accurate speech in real time without human help. Unlike some services, the physicians can speak normally […]

The post Amazon Debuts Service Enabling Doctors to Dictate Notes in Real Time appeared first on Karma.

]]> /amazon-debuts-service-enabling-doctors-to-dictate-notes-in-real-time/feed/ 0 Despite Concerns About Gene Editing, Venture Investors, Big Pharma Remain a Captive Audience /despite-concerns-about-gene-editing-venture-investors-big-pharma-remain-a-captive-audience/ /despite-concerns-about-gene-editing-venture-investors-big-pharma-remain-a-captive-audience/#respond Wed, 27 Nov 2019 16:18:18 +0000 /?p=13957 A year after a Chinese scientist unleashed a storm of condemnation by announcing the birth of a baby whose genes he had edited, the medical and scientific community has yet to agree on rules guiding research into the practice. Still, that hasn’t dimmed venture capitalists enthusiasm for the technology, with its potential to create medical […]

The post Despite Concerns About Gene Editing, Venture Investors, Big Pharma Remain a Captive Audience appeared first on Karma.

]]> /despite-concerns-about-gene-editing-venture-investors-big-pharma-remain-a-captive-audience/feed/ 0 Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/ /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/#respond Tue, 26 Nov 2019 21:49:14 +0000 /?p=13954 Stem cell biotech company Novoheart and pharmaceutical giant AstraZeneca announced they would be partnering to develop the first test tube model of human heart failure, also called heart-in-a-jar. The companies said they would use heart tissue engineered by Novoheart to emulate conditions faced by patients suffering from heart failure with preserved ejection fraction (HFpEF) and […]

The post Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model appeared first on Karma.

]]> /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/feed/ 0 How Mark Zuckerberg Wants to Fix Science /how-mark-zuckerberg-wants-to-fix-science/ /how-mark-zuckerberg-wants-to-fix-science/#respond Tue, 26 Nov 2019 21:23:46 +0000 /?p=13942 Mark Zuckerberg, Facebook’s embattled co-founder and CEO, isn’t just interested in creating the biggest ad machine and political platform in history. He also wants to fix and accelerate the rate of scientific discovery. In a video conversation published on Monday with Patrick Collison, CEO of Stripe, and Tyler Cowen, an economist from George Mason University, […]

The post How Mark Zuckerberg Wants to Fix Science appeared first on Karma.

]]> /how-mark-zuckerberg-wants-to-fix-science/feed/ 0 Blackstone Teams With Swiss Firm Ferring For $570 Million Effort to Make Cancer Killing Gene Therapy /blackstone-teams-with-swiss-firm-ferring-for-570-million-effort-to-make-cancer-killing-gene-therapy/ /blackstone-teams-with-swiss-firm-ferring-for-570-million-effort-to-make-cancer-killing-gene-therapy/#respond Mon, 25 Nov 2019 19:22:27 +0000 /?p=13908 Blackstone, which last year started up a life sciences investing arm, is pouring $400 million into a venture with a Swiss pharmaceutical firm to develop and commercialize a gene therapy for bladder cancer. Blackstone’s investment seeks to spur FerGene, a newly founded subsidiary of Ferring Pharmaceuticals, as it develops nadofaragene firadenovec, a virus-based therapy for […]

The post Blackstone Teams With Swiss Firm Ferring For $570 Million Effort to Make Cancer Killing Gene Therapy appeared first on Karma.

]]> /blackstone-teams-with-swiss-firm-ferring-for-570-million-effort-to-make-cancer-killing-gene-therapy/feed/ 0 Mursla Wants to Be the First Company to Sell Quantum Biology Product to Consumers /mursla-wants-to-be-the-first-company-to-sell-quantum-biology-product-to-consumers/ /mursla-wants-to-be-the-first-company-to-sell-quantum-biology-product-to-consumers/#respond Fri, 22 Nov 2019 18:29:23 +0000 /?p=13866 A recent number of studies and funding rounds offered a glimpse into what the new wave of quantum biology research may offer and how the new generation of innovative solutions may take shape. Mursla, a U.K.-based startup, is an early mover tapping concepts of quantum biology for commercial applications, specializing in early cancer detection. “Our […]

The post Mursla Wants to Be the First Company to Sell Quantum Biology Product to Consumers appeared first on Karma.

]]> /mursla-wants-to-be-the-first-company-to-sell-quantum-biology-product-to-consumers/feed/ 0 Seniors May Be Overpaying for Medicine, Study Looking at Medicare’s Use of Generics Suggests /seniors-may-be-overpaying-for-medicine-study-looking-at-medicares-use-of-generics-suggests/ /seniors-may-be-overpaying-for-medicine-study-looking-at-medicares-use-of-generics-suggests/#respond Thu, 21 Nov 2019 21:35:46 +0000 /?p=13852 Medicare may not be getting the best prescription drug deals it can, meaning senior citizens using the plan are overpaying, a new study suggests. Private insurance companies adopt cheaper generic drugs at a faster pace than government-run Medicare, a study by lobbying group Access for Affordable Medicines concludes. Generics are intended to be a lower-cost […]

The post Seniors May Be Overpaying for Medicine, Study Looking at Medicare’s Use of Generics Suggests appeared first on Karma.

]]> /seniors-may-be-overpaying-for-medicine-study-looking-at-medicares-use-of-generics-suggests/feed/ 0 GHO Capital, Spying European Healthcare Opportunities, Raises Record Fund /gho-capital-spying-european-healthcare-opportunities-raises-record-fund/ /gho-capital-spying-european-healthcare-opportunities-raises-record-fund/#respond Wed, 20 Nov 2019 21:59:21 +0000 /?p=13829 Private equity firm GHO Capital Partners, reflecting European investors’ bullishness for healthcare, topped expectations by raising almost $1.1 billion for its second fund.  The total, surpassing GHO’s $885 million goal, is a record for a fund targeting European healthcare, according to data from research group Prequin.  The U.K.-based European healthcare specialist raised twice the amount […]

The post GHO Capital, Spying European Healthcare Opportunities, Raises Record Fund appeared first on Karma.

]]> /gho-capital-spying-european-healthcare-opportunities-raises-record-fund/feed/ 0 Purdue Pharma Took a Page from Big Tobacco & Oil in Effort to Shift Blame in Oxycontin Deaths /purdue-pharma-took-a-page-from-big-tobacco-oil-in-effort-to-shift-blame-in-oxycontin-deaths/ /purdue-pharma-took-a-page-from-big-tobacco-oil-in-effort-to-shift-blame-in-oxycontin-deaths/#respond Tue, 19 Nov 2019 20:40:23 +0000 /?p=13806 Oxycontin maker Purdue Pharma cultivated sympathetic writers and funded think tanks as part of an aggressive media campaign aimed at countering negative stories about its blockbuster opioid, ProPublica reported. For nearly 20 years Purdue followed tactics similar to those of the oil and tobacco industries by promoting science that advanced its agenda and shifting blame, […]

The post Purdue Pharma Took a Page from Big Tobacco & Oil in Effort to Shift Blame in Oxycontin Deaths appeared first on Karma.

]]> /purdue-pharma-took-a-page-from-big-tobacco-oil-in-effort-to-shift-blame-in-oxycontin-deaths/feed/ 0